These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27903664)

  • 1. Practical considerations for therapies targeting the prostacyclin pathway.
    Farber HW; Gin-Sing W
    Eur Respir Rev; 2016 Dec; 25(142):418-430. PubMed ID: 27903664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.
    Lang IM; Gaine SP
    Eur Respir Rev; 2015 Dec; 24(138):630-41. PubMed ID: 26621977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond a single pathway: combination therapy in pulmonary arterial hypertension.
    Sitbon O; Gaine S
    Eur Respir Rev; 2016 Dec; 25(142):408-417. PubMed ID: 27903663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New horizons in pulmonary arterial hypertension therapies.
    Galiè N; Ghofrani AH
    Eur Respir Rev; 2013 Dec; 22(130):503-14. PubMed ID: 24293466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary arterial hypertension: tailoring treatment to risk in the current era.
    Gaine S; McLaughlin V
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29263175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future perspectives in pulmonary arterial hypertension.
    Simonneau G; Hoeper MM; McLaughlin V; Rubin L; Galiè N
    Eur Respir Rev; 2016 Dec; 25(142):381-389. PubMed ID: 27903660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?
    Seferian A; Simonneau G
    Eur Respir Rev; 2013 Sep; 22(129):217-26. PubMed ID: 23997048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic post-embolic pulmonary hypertension: a new target for medical therapies?
    Delcroix M
    Eur Respir Rev; 2013 Sep; 22(129):258-64. PubMed ID: 23997053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
    Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
    Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience.
    Sitbon O; Vonk Noordegraaf A
    Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28096285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A paradigm shift in pulmonary arterial hypertension management.
    Rubin LJ; Galiè N; Simonneau G; McLaughlin V
    Eur Respir Rev; 2013 Dec; 22(130):423-6. PubMed ID: 24293459
    [No Abstract]   [Full Text] [Related]  

  • 12. Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?
    Correale M; Montrone D; Ieva R; Di Biase M; Brunetti ND
    Clin Res Cardiol; 2013 May; 102(5):391-3. PubMed ID: 23389056
    [No Abstract]   [Full Text] [Related]  

  • 13. Pulmonary Arterial Hypertension in Women.
    Memon HA; Park MH
    Methodist Debakey Cardiovasc J; 2017; 13(4):224-237. PubMed ID: 29744015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombocytopenia During Prostacyclin Analogue Therapies of Pulmonary Arterial Hypertension-Possible Pathomechanisms and Implications.
    Grześk G; Karasek D; Kusiak M
    J Cardiovasc Pharmacol; 2020 May; 75(5):421-425. PubMed ID: 32379109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Severe Portopulmonary Hypertension With Dual Oral Therapy Before Liver Transplantation.
    Vionnet J; Yerly P; Aubert JD; Pascual M; Aldenkortt F; Berney T; Giostra E; Moradpour D; Schiffer E
    Transplantation; 2018 May; 102(5):e194. PubMed ID: 29485510
    [No Abstract]   [Full Text] [Related]  

  • 16. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
    Correale M; Ferraretti A; Monaco I; Grazioli D; Di Biase M; Brunetti ND
    Vasc Health Risk Manag; 2018; 14():253-264. PubMed ID: 30323613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal.
    Sitbon O; Baloira Villar A; Bauer F; Ekmehag B; Gin-Sing W; Jansson K; Kiely DG; Leuchte H; Manes A; Rosenkranz S; Escribano P
    Eur Respir Rev; 2012 Sep; 21(125):259-62. PubMed ID: 22941892
    [No Abstract]   [Full Text] [Related]  

  • 18. Oxidative and nitrosative signalling in pulmonary arterial hypertension - Implications for development of novel therapies.
    Hansen T; Galougahi KK; Celermajer D; Rasko N; Tang O; Bubb KJ; Figtree G
    Pharmacol Ther; 2016 Sep; 165():50-62. PubMed ID: 27216365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Treprostinil in Pediatric Pulmonary Hypertension: Case Reports and Review of the Literature.
    Gavotto A; Thomas F; Werner O; Moreau J; Amedro P
    J Cardiovasc Pharmacol; 2020 Jul; 76(1):23-31. PubMed ID: 32168152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evidence-based approach to the management of pulmonary arterial hypertension.
    Archer SL; Michelakis ED
    Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.